Biotechnology - neratinib

Filter

Current filters:

neratinib

Popular Filters

176 to 200 of 2104 results

Gilead announces three promotions in senior management team

Gilead announces three promotions in senior management team

28-01-2014

US biotech major Gilead Sciences (Nasdaq: GILD) has announced several promotions within the company's…

BiotechnologyBoardroomGilead SciencesUSA

NW Bio to expand manufacturing of DCVax products

27-01-2014

US biotech firm Northwest Biotherapeutics has entered into a set of agreements for large-scale expansion…

BiotechnologyDCVaxEuropeNorth AmericaNorthwest BiotherapeuticsProductionRegulationUSA

Chelsea Therapeutics names Joseph Oliveto as president and CEO

Chelsea Therapeutics names Joseph Oliveto as president and CEO

27-01-2014

US biotech firm Chelsea Therapeutics’ (Nasdaq: CHTP) has named Joseph Oliveto as president and chief…

BiotechnologyBoardroomChelsea TherapeuticsUSA

TiGenix to sell Dutch manufacturing facility to PharmaCell

24-01-2014

Belgian cell therapy firm TiGenix has signed an agreement for the sale of its state-of-the-art Dutch…

BiotechnologyChondroCelectMergers & AcquisitionsNorthern EuropePharmaCellProductionTiGenix

Gilead’s idelalisib shows promise in treating indolent non-Hodgkin lymphomas

Gilead’s idelalisib shows promise in treating indolent non-Hodgkin lymphomas

24-01-2014

Slow-growing, or indolent, non-Hodgkin lymphomas are difficult to treat, with most patients relapsing…

BiotechnologyGilead SciencesidelalisibOncologyResearch

Amgen’s evolocumab beats Zetia in Ph III GAUSS-2 trial for cholesterol reduction

Amgen’s evolocumab beats Zetia in Ph III GAUSS-2 trial for cholesterol reduction

24-01-2014

USA-based Amgen yesterday revealed positive results from the Phase III GAUSS-2 (Goal Achievement After…

AmgenBiotechnologyCardio-vascularevolocumabResearchZetia

BioLineRx gains orphan status for novel stem cell mobilization treatment

BioLineRx gains orphan status for novel stem cell mobilization treatment

23-01-2014

Israeli drug developer BioLineRx has received notice from the US Food and Drug Administration confirming…

BioLineRxBiotechnologyBL-8040Rare diseasesRegulationResearch

UK government’s Strategy for UK Life Sciences has made progress but must do more, says report

UK government’s Strategy for UK Life Sciences has made progress but must do more, says report

23-01-2014

A review of the UK government's Strategy for UK Life Sciences has found that eight out of the 13 initiatives…

BiotechnologyHealthcarePharmaceuticalPoliticsUK

Prothena to get $30 million upfront from Roche triggered by regulatory milestone

Prothena to get $30 million upfront from Roche triggered by regulatory milestone

23-01-2014

Clinical-stage biotech firm Prothena said today that it will receive the $30 million upfront payment…

BiotechnologyFinancialLicensingNeurologicalProthenaPRX002Roche

Heptares meets milestone in MedImmune research collaboration

Heptares meets milestone in MedImmune research collaboration

23-01-2014

UK-based drug company Heptares Therapeutics has successfully completed the research phase of its antibody…

AstraZenecaBiotechnologyHeptares TherapeuticsMedImmuneResearchUK

BioMarin buys rights to Repligen preclinical compounds

23-01-2014

BioMarin Pharmaceuticals has entered into an agreement to purchase from fellow USA-based Repligen Corp…

BioMarin PharmaceuticalBiotechnologyLicensingRare diseasesRepligen

New nanoparticle therapy reduces damage after heart attack

22-01-2014

Privately-held US biopharma company Cour Pharmaceutical Development reports the publication of new data…

BiotechnologyCardio-vascularCour Pharmaceutical DevelopmentResearch

Patrys shares rise as 10-year data shows PAT-SC1 improves survival

22-01-2014

Australian biotech company Patrys (ASX: PAB) has published 10-year follow up data for its product PAT-SC1…

AustraliaBiotechnologyOncologyPAT-SC1PatrysResearch

NICE recommends Sanofi’s Aubagio as new treatment option for MS

NICE recommends Sanofi’s Aubagio as new treatment option for MS

22-01-2014

In final guidance, UK drugs watchdog the National Institute for Health and Care Excellence (NICE) has…

AubagioBiotechnologyGenzymeNeurologicalNorthern EuropePricingRegulationSanofiUK

Nuevolution signs international deal to screen potential cancer drugs using DNA tags

Nuevolution signs international deal to screen potential cancer drugs using DNA tags

22-01-2014

An innovative screening technology that tags compounds with unique strands of DNA will be used to assess…

BiotechnologyDenmarkNuevolutionOncologyResearchUK

Domain Therapeutics opens North American subsidiary

20-01-2014

French biopharma company Domain Therapeutics, specializing in the R&D of new drug candidates targeting…

BiotechnologyCanadaDomain TherapeuticsManagementNorth America

iCo Therapeutics within reach of ‘holy grail’ cure in the $14 billion HIV market, says Edison

20-01-2014

Canadian biotech company iCo Therapeutics’s (iCO: TSX-V) compound AmpB could potentially allow the…

Anti-viralsBiotechnologyCanadaFinancialiCo TherapeuticsResearch

Gilead’s Sovaldi gains EC approval for chronic hepatitis C

Gilead’s Sovaldi gains EC approval for chronic hepatitis C

20-01-2014

US antivirals specialist Gilead Sciences has received marketing authorization from the European Commission…

Anti-viralsBiotechnologyEuropeGilead SciencesPricingRegulationSovaldi

MAb market for gastric and esophageal cancer expected to double by 2019

MAb market for gastric and esophageal cancer expected to double by 2019

18-01-2014

Due to favorable market conditions in terms of US pricing structures and the anticipated approval of…

BiotechnologyHerceptinMarkets & MarketingOncologyRoche

Nicox granted exclusive promotion and marketing rights for AMD test in North America

17-01-2014

French biotech firm NicOx SA (NYSE Euronext Paris: COX) and USA-based Sequenom (Nasdaq: SQNM) have entered…

BiotechnologyFranceLicensingNicOxOphthalmicsSequenomUSA

Shire sheds Dermagraft assets for $300 million in milestone payments

Shire sheds Dermagraft assets for $300 million in milestone payments

17-01-2014

Ireland-headquartered drugmaker Shire (LSE: SHP) has agreed to sell its Dermagraft (human fibroblast-derived…

BiotechnologyDermagraftDiabetesLicensingNorthern EuropeShire

ThromboGenics’ Jetrea gets positive reimbursement opinion in France

ThromboGenics’ Jetrea gets positive reimbursement opinion in France

17-01-2014

Belgian biotech firm ThromboGenics says that the Transparency Commission of the French National Health…

AlconBiotechnologyJetreaNovartisOphthalmicsPricingThromboGenics

176 to 200 of 2104 results

Back to top